Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRN-119 in Advanced Solid Tumors
NCT04905914Phase 2Completed
- Sponsor
- Aprea Therapeutics
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATRN-119 in solid tumor, sponsored by Aprea Therapeutics. Started Jan 2023; status: completed.
02
Drugs
ATRN-119
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04905914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905914.